Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2013


Stability Testing in Pharmaceutical Development and Manufacturing

14 May 2013 - 15 May 2013 - London, UK



Bookmark and Share


This course has been updated to reflect the recent changes in the pharmaceutical stability testing world.

The new course content will provide a comprehensive update on current trends which offer substantial potential savings in time and resources in a traditionally costly testing area. It will include opportunities for review of specific participant problems

The course will cover:

Recent regulatory changes affecting stability including

  • The implications of implementation of ICH Q7, Q8, Q9, Q10 and Q11 for stability testing
  • Changes to European GMP guidance with impact on stability testing including Annexe updates affecting product development, outsourcing and application of Quality Risk Management (QRM)
  • Product Quality Reviews and the interpretation of stability data.

Recent scientific developments with implications for stability, with a particular focus on cost reduction, shortening of development timelines, and improvements on existing interpretation systems

  • ASAP - using short term high stress testing to get accurate predictions of shelf life with a high degree of confidence - Freethink Technologies' ASAPprime
  • Low level impurities and their impact on product stability
  • Manipulation of tablet internal pH to improve product stability

Who Should Attend?

The course is designed for people working in:
  • Analytical Development
  • Analytical Chemistry
  • Stability Testing
  • Formulation Development
  • Regulatory Affairs
  • Pharmaceutical & Biopharmaceutical Production
  • Product Development
  • Technical Operations

Course Programme

DAY 1

The course will commence with registration and coffee at 8.30am, course proper at 9.00am and will finish at 5.00pm

Morning

Introductions

  • Quality by Design and the ICH updates QQ7, Q8, Q9, Q10 and Q11 - implications for stability testing

Afternoon

  • Changes to EU GMP guidance with implications for stability - Chapter 1 and Annexes
  • Product Quality Review and the interpretation of stability data
  • Delegate workshop - reviewing delegate-presented problems

DAY 2

Morning

  • Low level impurities and their impact on drug product stability.
  • ASAP - using short term, high stress testing to get accurate predictions of drug substance and drug product shelf life with high confidence using ASAPprime software
  • Bracketing and matrixing and accurate data interpretation, using the "Stability" software package from Arlenda

Afternoon

  • Manipulation of tablet internal pH to improve product stability
  • In Silico prediction of drug degradation pathways using the Zeneth software systems
  • Action Planning and Final Q&A. Delegates are encouraged to send data for analysis prior to the course

Additional Resources

Online access to comprehensive publications including all relevant guidance will be provided as well as colour copies of all presentations and case studies.



Further information
Scientific News
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Uncovering How Some Breast Cancers Resist Treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Activating Cancer-Killing Immune Cells
A UCL research team have discovered that cutting off a sleep-switch on immune cells inside a tumour wakes up the cells and enables the immune system to hunt down and destroy cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!